Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Yahoo Finance · Jul 31, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) authorization for its Phase 2a PRECISION-E2 clinical study evaluating Teverelix in women with moderate-to-severe symptomatic...
Not investment advice. Cached headline, not a full reprint.